Omalizumab, an anti-immunoglobulin E antibody: state of the art

A large number of trials show that the anti-immunoglobulin (Ig) E antibody omalizumab is very effective in patients with severe allergic asthma. This is acknowledged in consensus documents. The drug also has a good safety profile and a pharmacoeconomic advantage due to a reduction in the number of h...

Descripción completa

Detalles Bibliográficos
Autores principales: Incorvaia, Cristoforo, Mauro, Marina, Russello, Marina, Formigoni, Chiara, Riario-Sforza, Gian Galeazzo, Ridolo, Erminia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3923619/
https://www.ncbi.nlm.nih.gov/pubmed/24532966
http://dx.doi.org/10.2147/DDDT.S49409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3923619/
https://www.ncbi.nlm.nih.gov/pubmed/24532966
http://dx.doi.org/10.2147/DDDT.S49409

Ejemplares similares